135 related articles for article (PubMed ID: 10536419)
41. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
42. [Measurement of macrophage colony-stimulating factor during in-vitro fertilization and embryo transfer cycles].
Quan S; Wan L; Song L
Zhonghua Fu Chan Ke Za Zhi; 2000 Jan; 35(1):42-4. PubMed ID: 11831950
[TBL] [Abstract][Full Text] [Related]
43. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
45. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
[TBL] [Abstract][Full Text] [Related]
46. [Within-day and day-to-day variations of serum M-CSF levels in healthy volunteers].
Aihara T; Misago M; Hanamura T; Kikuchi M; Toshimitsu H; Ootani H; Chiba S; Eto S
Rinsho Byori; 1993 Mar; 41(3):268-72. PubMed ID: 8345656
[TBL] [Abstract][Full Text] [Related]
47. [The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor].
Inoue M; Inoue Y; Hiramatsu K; Tanaka Y; Yamasaki M; Ueda G; Minagawa J; Ozaki M; Yanagida T; Nishino H
Nihon Sanka Fujinka Gakkai Zasshi; 1984 May; 36(5):779-84. PubMed ID: 6736725
[TBL] [Abstract][Full Text] [Related]
48. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Fuith LC; Czarnecki M; Wachter H; Fuchs D
Obstet Gynecol; 1994 May; 83(5 Pt 1):801. PubMed ID: 8164949
[No Abstract] [Full Text] [Related]
49. Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma.
Marx D; Fattahi-Meibodi A; Kudelka R; Uebel T; Kuhn W; Meden H
Anticancer Res; 1998; 18(4B):2891-4. PubMed ID: 9713482
[TBL] [Abstract][Full Text] [Related]
50. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczynska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2004 Mar; 42(3):256-60. PubMed ID: 15080556
[TBL] [Abstract][Full Text] [Related]
51. Hematopoietic cytokines as tumor markers in gynecological malignancies: a multivariate analysis with ROC curve in endometrial cancer patients.
Lawicki S; Będkowska GE; Gacuta-Szumarska E; Szmitkowski M
Growth Factors; 2012 Feb; 30(1):29-36. PubMed ID: 22010785
[TBL] [Abstract][Full Text] [Related]
52. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
53. Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
Ławicki S; Czygier M; Bedkowska E; Wojtukiewicz M; Szmitkowski M
Pol Arch Med Wewn; 2008 Sep; 118(9):464-9. PubMed ID: 18846980
[TBL] [Abstract][Full Text] [Related]
54. [Serum level of the tumor marker CA 125 in ovarian pathology].
Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
[TBL] [Abstract][Full Text] [Related]
55. Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers.
Callet N; Delaunay J; Pichon MF
Eur J Gynaecol Oncol; 2000; 21(2):135-40. PubMed ID: 10843471
[TBL] [Abstract][Full Text] [Related]
56. [Macrophage colony-stimulating factor for treatment of prostatic cancer with bone metastases].
Hayashi T; Kakehi R
Hinyokika Kiyo; 1993 Jan; 39(1):101-5. PubMed ID: 8460579
[TBL] [Abstract][Full Text] [Related]
57. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
[TBL] [Abstract][Full Text] [Related]
58. [The plasma levels and diagnostic utility of selected hematopoietic growth factors in endometrial cancer patients and with myoma uteri].
Ławicki S; Bedkowska GE; Gacuta-Szumarska E; Czygier M; Szmitkowski M
Pol Merkur Lekarski; 2010 May; 28(167):354-8. PubMed ID: 20568396
[TBL] [Abstract][Full Text] [Related]
59. Binding of macrophage colony-stimulating factor to serum proteins.
Ohtsuki T; Hatake K; Ikeda M; Yamada M; Motoyoshi K; Miura Y
Exp Hematol; 1996 Feb; 24(2):101-7. PubMed ID: 8641330
[TBL] [Abstract][Full Text] [Related]
60. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.
Scholl SM; Bascou CH; Mosseri V; Olivares R; Magdelenat H; Dorval T; Palangié T; Validire P; Pouillart P; Stanley ER
Br J Cancer; 1994 Feb; 69(2):342-6. PubMed ID: 8297732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
